Ruchun Ji

Ruchun Ji's representative experience includes advising:

Mergers & Acquisitions and Private Equity

• Zylox-Tonbridge Medical Technology in a $15 million PIPE transaction to purchase stock of Avinger, Inc.
• SanReno Therapeutics in its acquisition by Novartis.
• Resolian in its acquisition of Denali Medpharma.
• Inspiration Capital Partners in its leveraged acquisition of Antute (Beijing) Technology Limited.
• Venus Medtech in its $300 million acquisition of Cardiovalve Ltd.
• Vector Capital in the sale of CollabNet to TPG and other transactions.

Capital Markets

• Zhaoke Ophthalmology in its US$250 million initial public offering.
• Ocumension Therapeutics in its approximately US$182.5 million IPO.
• Nektar Therapeutics in multiple public offerings for aggregate proceeds of approximately US$600 million.

Emerging Companies and Venture Capital

• OnCusp Therapeutics in a US$100 million Series A financing round.
• Vivo Capital as lead investor in the US$75 million Series A financing for Ablaze Pharmaceuticals.
• Venrock Partners in the US$80 million preferred stock financing of Biohaven Pharmaceutical.

Licensing and IP

• I-Mab in its strategic collaboration with Jumpcan Pharmaceutical Group.
• NeuroFront in its exclusive licensing agreement with Neurolief.
• Alebund Pharmaceuticals in its option and license agreement with Chugai.